International Cancer Conference Journal最新文献

{"title":"Surgical resection of an adrenocorticotropic hormone-producing pulmonary typical carcinoid with mediastinal lymph node metastasis and high programmed death-ligand 1 expression.","authors":"Masakazu Matsuda, Fumihiko Kinoshita, Yukina Takeichi, Koichi Igata, Naoya Iwamoto, Taichi Matsubara, Kazuki Takada, Mikiko Hashisako, Shinichi Aishima, Yoshinao Oda, Tomoyoshi Takenaka, Tomoharu Yoshizumi","doi":"10.1007/s13691-026-00844-8","DOIUrl":"https://doi.org/10.1007/s13691-026-00844-8","url":null,"abstract":"<p><p>The programmed death-ligand 1 positivity rate in typical carcinoid is generally low; however, cases with programmed death-ligand 1 expression are more frequently associated with lymph node metastasis and have a poorer prognosis. While immune checkpoint inhibitors were incorporated into adjuvant chemotherapy regimens for programmed death-ligand 1-positive non-small cell lung cancer, their efficacy in pulmonary carcinoids remains unclear. A 47-year-old woman presented to a local clinic with moon face. Laboratory testing revealed elevated levels of adrenocorticotropic hormone and cortisol and adrenocorticotropic hormone-dependent Cushing's syndrome was suspected. For further evaluation, the patient was referred to our hospital. Computed tomography revealed a nodule in the left lower lobe of the lung and enlargement of the left hilar lymph node, suggesting ectopic Cushing's syndrome. Left lung cancer (cT1bN1M0, cStage IIB) was suspected, and the patient underwent robot-assisted thoracoscopic left lower lobectomy with ND2a-2 lymph node dissection for diagnostic and therapeutic purposes. Pathological examination confirmed a diagnosis of typical carcinoid (pT1bN2M0, pStage IIIA) with high programmed death-ligand 1 expression. Considering the presence of mediastinal lymph node involvement and programmed death-ligand 1 expression, the patient received four courses of cisplatin and vinorelbine, followed by treatment with atezolizumab. Postoperatively, her adrenocorticotropic hormone levels normalized, and the patient has been alive 18 months postoperatively without recurrence. Programmed death-ligand 1-positive typical carcinoids are associated with a higher frequency of lymph node metastasis and poorer prognosis. <i>Additional case investigations are required to assess the efficacy of immune checkpoint inhibitors in typical carcinoid.</i></p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"217-221"},"PeriodicalIF":0.5,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three cases of esophagorespiratory fistula following neoadjuvant DCF therapy for resectable esophageal cancer.","authors":"Asuma Ide, Hironori Tsujimoto, Seiichiro Fujishima, Risa Kariya, Naoyuki Uehata, Takafumi Suzuki, Hiroki Tashiro, Keita Kouzu, Yoshihisa Yaguchi, Hideki Ueno","doi":"10.1007/s13691-025-00843-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00843-1","url":null,"abstract":"<p><p>Neoadjuvant chemotherapy with 5-FU, cisplatin, and docetaxel (DCF) is standard for resectable esophageal cancer in Japan but is linked to severe adverse events. We report three cases of esophagorespiratory fistulas (ERFs) occurring during DCF therapy. Case 1: A 72-year-old woman (cStage II) developed fever after two DCF cycles. CT and esophagography confirmed an ERF. An esophageal stent was placed, but she later opted for best supportive care. Case 2: A 53-year-old man (cStage IIIB) developed pneumatosis intestinalis and pneumonia nine days into DCF. Imaging confirmed an ERF. He received a stent on day 19 and continued chemotherapy for over a year. Case 3: A 65-year-old man (cStage IIIA) presented with dyspnea eight days after starting DCF. CT revealed pneumothorax and pyothorax. A stent was placed on day 19. His condition initially improved but later declined, leading to best supportive care. DCF therapy may enhance survival but carries significant risk for ERFs. Early recognition of symptoms and rapid intervention are critical to managing complications.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"210-216"},"PeriodicalIF":0.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinoma.","authors":"Haruka Anzai, Chihiro Miwa, Sadahisa Ogasawara, Makoto Fujiya, Hiroki Kurosaki, Takahiro Tsuchiya, Ryohei Yoshino, Keiichi Katayama, Midori Sawada, Teppei Akatsuka, Ryo Izai, Takuya Yonemoto, Sae Yumita, Keisuke Koroki, Masanori Inoue, Masato Nakamura, Naoya Kanogawa, Shingo Nakamoto, Hirokazu Makishima, Makoto Shinoto, Masaru Wakatsuki, Shigeru Yamada, Hitoshi Ishikawa, Jun Kato","doi":"10.1007/s13691-025-00839-x","DOIUrl":"https://doi.org/10.1007/s13691-025-00839-x","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with advanced cases often presenting macrovascular invasion (MVI) or extrahepatic spread (EHS), limiting curative options. Latest systemic therapies, such as atezolizumab plus bevacizumab, have demonstrated potential in converting advanced HCC into treatable states. Carbon ion radiotherapy (C-ion RT), with its superior dose localization and biological effectiveness, has emerged as a promising treatment for advanced HCC. This retrospective exploratory case series reviewed eight patients with advanced HCC who received C-ion RT following systemic therapy at a single Japanese institution between 2021 and 2023. Data collection and follow-up were completed in October 2024. During the study period, 188 patients with advanced HCC received systemic therapy at our institution. Among these, 176 patients (93.6%) continued systemic therapy alone or received additional transarterial chemoembolization (TACE) for local disease control, while 12 patients (6.4%) were evaluated for curative-intent local therapy through multidisciplinary discussion. Patients were considered for conversion therapy after showing tumor shrinkage or loss of contrast enhancement during systemic therapy, but surgical resection was judged infeasible due to poor liver function or surgical tolerance. Therefore, C-ion RT was selected to treat all residual intrahepatic lesions. Clinical characteristics, treatment details, radiological responses, and safety outcomes were evaluated. The median age was 71 years, with 62.5% presenting MVI and 62.5% having tumors ≥ 90 mm in diameter. Systemic therapy included atezolizumab plus bevacizumab in seven cases and lenvatinib in one case. Following systemic therapy, C-ion RT achieved radiological cancer-free (rCF) status in five patients, including four with MVI and three with major portal vein invasion (Vp4). No clinically meaningful deterioration in liver function was observed during treatment, and adverse events were minimal. Patients achieving rCF maintained short-term disease control. Median follow-up was 11 months (range, 5-16). This exploratory case series suggests that C-ion RT following systemic therapy may be a feasible and safe local consolidation approach for highly selected patients with advanced HCC. C-ion RT achieved short-term local control without deterioration of liver function in this small cohort. Given the limited sample size and follow-up duration, these findings are preliminary and warrant validation in prospective studies with larger cohorts to establish its role in multidisciplinary management.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-025-00839-x.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"195-202"},"PeriodicalIF":0.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of perihilar cholangiocarcinoma with peritoneal dissemination that achieved a pathological complete response using immune checkpoint inhibitors: A case report.","authors":"Takehiko Saijo, Hideaki Sato, Shuichi Aoki, Masahiro Iseki, Mika Ando, Yuichiro Umino, Mitsuhiro Shimura, Koetsu Inoue, Daisuke Douchi, Takayuki Miura, Shimpei Maeda, Masaharu Ishida, Masamichi Mizuma, Kazuhiro Kikuta, Atsushi Masamune, Keigo Murakami, Toru Furukawa, Michiaki Unno","doi":"10.1007/s13691-025-00842-2","DOIUrl":"https://doi.org/10.1007/s13691-025-00842-2","url":null,"abstract":"<p><p>Surgical resection is considered the only potentially curative treatment for biliary tract cancer (BTC). However, for patients with locally advanced or metastatic BTC, systemic chemotherapy remains the primary therapeutic option. Historically, chemotherapies such as gemcitabine plus cisplatin (GC), gemcitabine plus S-1, and GC plus S-1 have been employed; however, the prognosis remains poor. Recently, combined therapy with immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic approach for unresectable BTC. In cases with long-term efficacy to systemic chemotherapy, sequential surgical resection, known as conversion surgery, has also shown potential to improve overall outcomes in unresectable BTC. This case report presents a case of advanced perihilar cholangiocarcinoma with histologically confirmed peritoneal dissemination that achieved a pathological complete response after combination therapy with GC and durvalumab, followed by conversion surgery. Achieving a pathological complete response in the presence of peritoneal dissemination is rare. This case provides valuable insights into treatment strategies for this aggressive malignancy, demonstrating that a pathological complete response is possible even in the presence of peritoneal dissemination.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"203-209"},"PeriodicalIF":0.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.","authors":"Vincenzo Terrano, Erica Perri, Chiara Cioffo, Giusi Mastroianni, Maria Antonina Palumbo, Fortunato Ciardiello, Teresa Troiani, Stefania Napolitano","doi":"10.1007/s13691-025-00833-3","DOIUrl":"https://doi.org/10.1007/s13691-025-00833-3","url":null,"abstract":"<p><p>This case report describes the clinical management of a 68-year-old man with concurrent invasive melanoma and metastatic castration-resistant prostate cancer (mCRPC). Initially diagnosed with BRAF V600E-mutated melanoma, he received Dabrafenib and Trametinib. Later, prostate cancer was diagnosed with bilateral pulmonary metastases. Despite initial treatment with Triptorelin, Docetaxel, and Abiraterone, disease progression occurred. A liquid biopsy revealed an extremely high Tumor Mutational Burden (TMB) and mutations including <i>POLE, BRCA2, ATM, and TP53.</i> Due to the high TMB, off-label Pembrolizumab was initiated. Radiological evaluations at 3 and 6 months showed a marked response, with disappearance of target lung metastases and durable remission maintained through February 2025. Only grade 1 asthenia was reported, without significant treatment interruptions. This case illustrates the value of precision medicine and the role of liquid biopsy in guiding immunotherapy decisions for complex oncological cases. It supports the relevance of molecular profiling in selecting effective treatments beyond standard indications.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"189-194"},"PeriodicalIF":0.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic calcification due to diffuse lytic skeletal metastases, a rare presentation of breast cancer unveiled by bone scintigraphy and CT scan.","authors":"Reihaneh Mohammadhosseini, Leila Karimi, Parva Javanshayani, Hadi Milani, Mohammadali Ghodsirad","doi":"10.1007/s13691-025-00793-8","DOIUrl":"https://doi.org/10.1007/s13691-025-00793-8","url":null,"abstract":"<p><p>A 57-year-old woman with newly diagnosed breast cancer presented with diffuse skeletal pain, predominantly in the spine. Imaging, including whole-body bone scintigraphy, revealed multiple bony lesions in the skull, spine, ribs, pelvis, and femora, indicating widespread bone metastasis. Additionally, diffuse calcification was observed in the lungs, heart, and stomach, consistent with metastatic calcification. However, CT scans only showed diffuse lytic-sclerotic lesions in the skeleton without evidence of visceral calcification. The laboratory tests revealed elevated serum calcium, phosphorus, and creatinine levels, with normal parathyroid hormone (PTH) levels. This case underscores the critical role of bone scintigraphy in the early diagnosis and monitoring of metastatic bone disease in breast cancer patients. It highlights the superiority of bone scintigraphy over CT scans in detecting early-stage visceral calcification, emphasizing the importance of early recognition and management of metastatic calcification and hypercalcemia in cancer patients.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"175-181"},"PeriodicalIF":0.5,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topic: invasive adenocarcinoma of the lungs in a 17 year old adolescent child in a suburban hospital: A case report.","authors":"Ohonsi Abimbola Ajoke, Akerele Johnbull Mazor, Oyewusi Magdalene Ayienale, Alli Jeremiah Samuel, Orji-Okhueleigbe Augusta Adesua, Ogbogu Michael Izunwanneka, Owolabi Doubra Orherhe","doi":"10.1007/s13691-025-00841-3","DOIUrl":"https://doi.org/10.1007/s13691-025-00841-3","url":null,"abstract":"<p><p>Primary lung cancer is rare in pediatric patients. Patients generally present with nonspecific and indistinct clinical symptoms, which usually cause a delay in diagnosis. We report a case of adenocarcinoma in a 17 year-old adolescent child who presented with chronic productive cough, difficulty with breathing, haemoptysis, orthopnoea, weight loss, oedema of the lower limbs and knee joints. He was chronically ill looking with obvious bony prominences, grade 4 digital clubbing, and dull percussion notes and reduced breath sounds in the lower right lung zone. The preliminary diagnosis was lung abscess and pulmonary TB but Nucleic Acid Amplification Test (gene Xpert) and microscopy for acid-fast bacilli (AFB) were negative. Chest radiography revealed a solitary nodule in the right mid-lung zone, while chest CT revealed right lobar bronchiectasis. The patient was treated with anti-heart failure drugs, antibiotics, antifungal medications, blood transfusion, and physiotherapy. He also underwent a thoracotomy and right lower lung lobectomy. The edema resolved following the initial treatment, but the cough and difficulty with breathing persisted until the patient underwent right lobectomy. Symptoms resurfaced 3 weeks after lobectomy. Histological results showed invasive adenocarcinoma of the lung; thus, a definitive diagnosis of Invasive Adenocarcinoma of the lung was made. Patients and caregivers were counseled regarding the diagnosis and need for chemotherapy, patient died four months after the establishment of diagnosis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"182-188"},"PeriodicalIF":0.5,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of thymic carcinoma harboring an <i>FGFR3</i> S249C mutation with durable disease control on lenvatinib.","authors":"Noriko Bando, Hirokazu Ogino, Kojin Murakami, Masami Wadatsu, Yuki Tsukazaki, Yohei Yabuki, Tatsuya Kajimoto, Rikako Matsumoto, Saki Harada, Yutaka Morita, Ryohiko Ozaki, Atsushi Mitsuhashi, Seidai Sato, Satoshi Sakaguchi, Masaki Hanibuchi, Yasuhiko Nishioka","doi":"10.1007/s13691-025-00836-0","DOIUrl":"https://doi.org/10.1007/s13691-025-00836-0","url":null,"abstract":"<p><p>Thymic carcinoma is a rare and aggressive malignancy with limited treatment options, resulting in a poor prognosis. Lenvatinib, a small-molecule inhibitor targeting multiple receptor tyrosine kinases, including fibroblast growth factor receptors (FGFRs), has been approved for thymic carcinoma that progresses following platinum-based chemotherapy. However, the identification of predictive biomarkers for its efficacy remains an unmet medical need. We herein present a case of 67-year-old man with advanced thymic carcinoma who was treated with carboplatin plus paclitaxel as first-line therapy. Lenvatinib, administered as second-line therapy, achieved a durable disease control that was maintained for over 20 months-exceeding the previously reported median progression-free survival. Comprehensive genomic profiling (CGP) using the FoundationOne^® CDx assay identified an oncogenic <i>FGFR3</i> S249C mutation. The case, together with supporting literature, suggests the potential role of <i>FGFR3</i> mutations as therapeutic targets in thymic carcinoma. Furthermore, the presence of oncogenic mutations in lenvatinib-targeted genes may serve as predictive biomarkers for durable disease control. Given the limited availability of methods to detect oncogenic mutations, including FGFR3, in patients with thymic carcinoma, early implementation of CGP testing-even in the frontline setting-may be warranted in the future.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"160-165"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal adenocarcinoma with a yolk sac tumor component: A rare case report and review of the literature.","authors":"Sato Nishida, Tomohiro Takeda, Tatsuya Shonaka, Shoichiro Mizukami, Masahide Otani, Mizuho Ohara, Chikayoshi Tani, Kimiharu Hasegawa, Yuki Kamikokura, Mishie Tanino, Hideki Yokoo","doi":"10.1007/s13691-025-00831-5","DOIUrl":"https://doi.org/10.1007/s13691-025-00831-5","url":null,"abstract":"<p><p>Yolk sac tumor (YST) occurs primarily in the gonads but rarely outside the gonads. They typically arise in the midline location, and there are only a few reports describing the colon and rectum as the primary sites of YST. Additionally, colorectal cancers containing YST-like components are rare, and in other organs, including the stomach, it is more common to describe such lesions as \" yolk sac tumor-like carcinoma\". Here, we report a case of colorectal adenocarcinoma with a YST-like component arising in the rectum. This is the seventh reported case of colorectal YST-like carcinoma. A 66-year-old man presented to our hospital with the chief complaint of anal bleeding. Colonoscopy revealed a 25 × 20 mm tumor located 5 cm above the anal verge. Biopsy results showed moderately differentiated tubular adenocarcinoma, cT3, cN2b, cM0, and cStage IIIC (UICC 8th edition). Subsequently, a laparoscopic abdominoperineal resection was performed. A histopathological examination of the resected specimen revealed findings of adenocarcinoma and YST-like component. Immunostaining for mismatch repair proteins revealed no abnormalities. The tumor was positive for the <i>KRAS</i> G12S mutation, and negative for the <i>BRAF</i> mutation. The overall diagnosis was adenocarcinoma with a YST-like component, pT3, pN2a, cM0, and pStage IIIB (UICC 8th edition). Six months after the surgery, metastasis was found in the liver, but at the request of the patient and their family, the decision was made not to undergo any aggressive treatment. We describe the clinical and pathological features of colorectal YST-like carcinoma that aid in its accurate diagnosis and provide treatment suggestions.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"138-146"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report.","authors":"Desiree Rafizadeh, D Kaakour, S Sun, J Herman, T Kain, A Rezazadeh Kalebasty","doi":"10.1007/s13691-025-00834-2","DOIUrl":"https://doi.org/10.1007/s13691-025-00834-2","url":null,"abstract":"<p><p>Prostate specific membrane antigen (PSMA) Lutetium-177 (Lu-177) therapy is a relatively new theranostic treatment using a targeted radioligand therapy in the treatment of metastatic prostate cancer. PSMA-Lu177 has been approved by the FDA for treatment of prostate cancer in the metastatic castrate resistant setting. Here, we present the case of a 90-year-old man with metastatic castrate resistant prostate cancer (mCRPC) and primary resistance to androgen deprivation, second-generation androgen receptor inhibitors, and docetaxel chemotherapy. Despite the lack of response to prior lines of therapy, the patient demonstrated a rapid response to PSMA-Lu177 therapy with a substantial drop in PSA level, starting from the first cycle.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"154-159"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}